MENU

CIDEB siRNA: Regeneron’s MASLD liver fat reduction trial results

FT.com(GlobeNewswire / Regeneron Pharmaceuticals) USA
Overview
A single subcutaneous dose of CIDEB siRNA reduced liver fat by 58-80% and improved liver injury markers in MASLD patients through week 36. The trial demonstrated that 62% of recipients achieved normalized liver fat levels, suggesting a potential for twice-yearly dosing.
In Depth

Key Findings

In a first-in-human trial, a single subcutaneous administration of CIDEB siRNA resulted in rapid and durable reductions in liver fat, with decreases of 58-80% observed at week 36. These results were sustained from an initial reduction of 49-72% at week 6, as measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF). In contrast, the placebo group showed a mean decrease of 2.9% at week 36. Notably, 62% of CIDEB siRNA recipients achieved normalized liver fat (defined as under 5% by MRI-PDFF), while 93% saw reductions of ≥30%.

Technical Details

The Phase 1/2 trial evaluated four dose levels of CIDEB siRNA (n=30 per group) against a placebo (n=10) in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). CIDEB siRNA is a first-in-class, liver-targeted small interfering RNA designed to mimic protective effects of rare CIDEB gene mutations discovered by the Regeneron Genetics Center. Beyond fat reduction, the trial observed sustained improvements in liver injury markers through week 36, including reductions in mean alanine aminotransferase (ALT) and directionally similar changes in aspartate aminotransferase (AST) levels.

Background & Context

MASLD ranges from simple fatty liver to metabolic dysfunction-associated steatohepatitis (MASH), a progressive fibrotic disease affecting approximately 13 million U.S. adults. MASH is characterized by inflammation and cell damage that can lead to cirrhosis or liver cancer. The source notes that previously approved MASH therapies have reached mean liver fat reductions of 47-57% at approximately one year.

Significance & Outlook

The safety profile showed adverse events were generally similar between the siRNA and placebo groups, with most being mild or moderate. No nausea or vomiting was reported, addressing a known limitation of other therapies. One severe event of hyperglycemia occurred but was attributed to adult-onset Type 1 diabetes rather than the study drug. Regeneron is currently recruiting for Phase 2a, Phase 2b, and Phase 3 trials to evaluate longer-term safety and histologic outcomes.

Source: https://markets.ft.com/data/announce/full?dockey=1330-9872883en-3MNI6QMM7DHVQKKI3GI5AB6UVP

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC